Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00841321 · ClinicalTrials.gov registry record · Phase 2
Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis and Cognitive Ability, General, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT00841321 is a Phase 2 study of Multiple Sclerosis and Cognitive Ability, General that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 120 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00841321, a Phase 2 study of Multiple Sclerosis and Cognitive Ability, General, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if treatment with Ginkgo improves cognitive function in people with multiple sclerosis who have cognitive problems.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ginkgo biloba
Study Locations (2)
Oregon
- Portland VA Medical Center, Portland, OR - Portland
Washington
- VA Puget Sound Health Care System, Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00841321
The ClinicalTrials.gov registry entry for NCT00841321 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00841321 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Oregon, Washington.
Frequently Asked Questions
What is clinical trial NCT00841321 about?
NCT00841321 is a clinical study titled "Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis". The purpose of this study is to see if treatment with Ginkgo improves cognitive function in people with multiple sclerosis who have cognitive problems.
What is the current status of trial NCT00841321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2009-01. Estimated completion is 2010-12.
What conditions does trial NCT00841321 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Cognitive Ability, General.
What interventions are being tested in trial NCT00841321?
The interventions under investigation include: Placebo (DRUG), Ginkgo biloba (DRUG).
Who is sponsoring clinical trial NCT00841321?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00841321 being conducted?
This trial has 2 study locations across Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.